Antiplatelet drug 3rd generation Reversible ADP P2Y12 Receptor Antagonist

Acute Coronary Syndrome (ACS) including STEMI, NSTEMI, and Unstable Angina Secondary prevention in patients with history of MI (to reduce risk of cardiovascular death) / Can be used in percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG)

Each film coated tablet contains Ticagrelor INN 90 mg.

1*10 Tablets

Loading dose: 180 mg orally once (usually at hospital admission for ACS) Maintenance dose: 90 mg orally twice daily

contraindicated in case of - any hypersensitivity to ticagrelor or to any of the excipients, peptic ulcer bleeding (peptic ulcer),history of intracranial haemorrhage, moderate to severe hepatic impairment, co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazana

Bleeding (major & minor), dyspnea, headache, cough, dizziness, nausea, atrial fibrillation, hypertension, diarrhea, back pain, hypotension, fatigue, chest pain.

CYP3A inhibitors: Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin). CYP3A inducers: Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin, carbamazepine and phenobarbital). Aspirin:Use of Ticagrelor with aspirin maintenance doses above 100 mg reduced the effectiveness of Ticagrelor. Simvastatin, lovastatin: Ticagrelor will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg. Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in ticagrelor therapy. Other Concomitant Therapy: Ticagrelor can be administered with unfractionated or low-molecular-weight heparin, GPIIb /IIIa inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers.

Aristopharma Ltd., Bangladesh.